KRAS and non-small cell lung carcinoma: We previously reported that adagrasib demonstrated potent preclinical activity in multiple preclinical BM models of NSCLC harboring KRAS-G12C and preliminary clinical efficacy in patients with KRAS-G12C brain metastatic NSCLC [6], leading to inclusion in a genomically-guided clinical trial for patients with BM (NCT03994796, Alliance A071701).